Attralus Stock
HealthTechLooking to sell Attralus stock or options?
Attralus is engaged in creating immunotherapies and an imaging diagnostic platform aimed at treating multiple systemic amyloid diseases. The company's focus is on developing treatments to eliminate amyloid fibrils in patients suffering from systemic amyloid conditions such as light chain, transthyretin, and LECT2 amyloidosis. This enables the healthcare sector to provide more effective treatments for amyloidosis patients.
Investors Include:
Samsara BioCapital, Logos Capital, Bristol-Myers Squibb, Surveyor Capital, LifeSci Venture Partners, Redmile Group, Vivo Capital, Janus Henderson Investors, Sarissa Capital Management, QB3, venBio, Biobrit, Citadel Enterprise Americas, Yarrow Capital, Alpha Wave Global.